Novartis and Matchpoint Therapeutics Announce $1.06B Collaboration to Develop Oral Covalent Inhibitor for Autoimmune Diseases

▎Armstrong

On July 24, 2025, Novartis announced a collaboration with Matchpoint Therapeutics to jointly develop novel small-molecule covalent inhibitors targeting transcription factors for the treatment of inflammatory diseases. Under the agreement, Novartis will pay $60 million upfront and up to $1 billion in milestone payments, including option exercise fees.

Matchpoint Therapeutics, founded in 2021, has an ACE technology platform that integrates machine learning, chemical proteomics, and compound libraries to screen for covalent small-molecule inhibitors targeting difficult-to-drug targets.

In October 2022, Matchpoint Therapeutics completed a $100 million Series A financing round, with investors including venture capital funds and industry players Sanofi and Vertex.

Summary

Inflammatory diseases are one of the key focus areas for Novartis. Its marketed blockbuster products include IL-17 antibodies and CFB inhibitors, while its important R&D pipelines encompass BTK inhibitors, BAFFR antibodies, CD19 CAR-T, IL-18/IL-1β bispecific antibodies, NLRP3 inhibitors, and more. This collaboration signifies Novartis' increased expansion into the field of autoimmune small-molecule drugs.